at 2.02

Public offering closed now, finally. Usually a time to pounce.

Good luck to all. (I need it with this one......)

========================

Ever hopefull Insmed......

Insmed Pharmaceuticals is a development stage pharmaceutical company
that is developing drugs to treat metabolic and endocrine diseases
associated with insulin resistance. The company's first drug candidate,
INS-1, is currently targeted towards the treatment of type 2 diabetes
and polycystic ovary syndrome. The company is currently conducting
multi-center phase II clinical trials for both indications. The
company's objective is to establish a leading position in the treatment
of metabolic and endocrine diseases.